Merck & Co Inc (MRK.N)
47.33USD
1:30am IST
$2.12 (+4.69%)
$45.21
$45.20
$47.38
$45.19
9,904,221
3,752,979
$48.78
$37.02
MRK.N
About
Overall
| Beta: | 0.57 |
| Market Cap (Mil.): | $136,516.70 |
| Shares Outstanding (Mil.): | 3,019.61 |
| Dividend: | 0.43 |
| Yield (%): | 3.80 |
Financials
| MRK.N | Industry | Sector | |
|---|---|---|---|
| P/E (TTM): | 23.04 | 35.67 | 35.85 |
| EPS (TTM): | 1.96 | -- | -- |
| ROI: | -- | 19.40 | 18.76 |
| ROE: | -- | 20.11 | 19.57 |
Merck sales rep alleges sexual bias, seeks over $100 mln
May 9 - A senior sales representative for Merck & Co has sued the drugmaker for more than $100 million, alleging the drugmaker discriminates against female employees in terms of pay and advancement, particularly pregnant employees and female employees with children.
Fitch Affirms Merck & Co.'s IDR at 'A+'; Outlook Negative
(The following statement was released by the rating agency) CHICAGO, May 03 (Fitch) Fitch Ratings has affirmed Merck & Co.'s (Merck) ratings, including the Issuer Default Rating (IDR) at 'A+'. The Rating Outlook is revised to Negative from Positive. A full list of ratings affirmed is listed below. The ratings apply to approximately $20.5 billion in outstanding debt. KEY RATING DRIVERS Leveraging Share-Buybacks Pressure Credit Profile On April 1, Merck announced the expansion of its share re
Wall Street drops on data, earnings; Facebook up late
NEW YORK - Stocks fell sharply on Wednesday as the latest economic data continued a trend of indicators pointing to anemic growth while bellwether companies disappointed on revenue. | Video
Wall St dips as Merk drags; Fed on tap
NEW YORK - Wall Street edged lower at the open on Wednesday, weighed by weak results from Merck as investors waited to hear from the U.S. Federal Reserve on the state of the economy.
UPDATE 3-Merck's Januvia diabetes drug lags, 2013 forecast cut
May 1 - Merck & Co Inc reported a surprising drop in quarterly sales of diabetes medicine Januvia, its biggest product and a frequent driver of quarterly earnings, and the drugmaker cut its full-year profit forecast on Wednesday.
US STOCKS-Wall St down on weak data, earnings; Fed on tap
* U.S. companies hire less, manufacturing growth slows in April
REFILE-US STOCKS SNAPSHOT - Wall St dips as Merck drags; Fed on tap
NEW YORK, May 1 - Wall Street edged lower at the open on Wednesday, weighed by weak results from Merck as investors waited to hear from the U.S. Federal Reserve on the state of the economy.
US STOCKS-Futures slip ahead of open on Merck, ADP; Fed on tap
* U.S. Fed expected to maintain $85 bln/month in bond buys
BRIEF-Merck shares down 2.1 pct premarket
NEW YORK, May 1 - Merck & Co Inc : * Shares down 2.1 percent in premarket trading after results
Merck first-quarter sales disappoint
May 1 - Merck & Co Inc reported lower than expected first quarter sales, as generic competition hurt demand for its Singulair asthma drug and the stronger dollar hit overseas sales of its medicines.
Competitors
| Price | Change | |
|---|---|---|
| Johnson & Johnson (JNJ.N) | $88.59 | +0.58 |
| Pfizer Inc. (PFE.N) | $28.78 | +0.08 |
| Abbott Laboratories (ABT.N) | $37.72 | -0.09 |
| Eli Lilly & Co. (LLY.N) | $55.14 | +0.12 |
| Bristol Myers Squibb Co. (BMY.N) | $44.06 | +0.30 |
| Bristol Myers Squibb Co. (BMY_p.N) | $567.60 | 0.00 |
Earnings vs. 
Estimates
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
